Mast cells, which are abundant in the airways of asthmatic individuals, act as first responders to viral infections by ...

The table is a review of notable updates that occurred in February 2025 for investigational products in development.

Shenzhen Zhongge Biotechnology Co. Ltd. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to an interleukin-1 ...

Children and adolescents in the U.S. who consume higher amounts of dietary energy have a lower risk of asthma, but this ...

IL-23, or IL-17 reduced serious infections, while tofacitinib increased infection risk, according to one study.

The data from the Phase 1/1b clinical trial of soquelitinib in patients with T cell lymphoma continues to demonstrate strong indications of anti-tumor activity in a significant number of patients,” ...

Q4 2024 Results Conference Call March 20, 2025 8:00 AM ET. Company Participants. Andrew Funderburk - Senior Vice President, Investor Re ...

Scientists at Guangzhou Imd Therapeutics Co. Ltd. and Pamplona Therapeutics (Shenzhen) Co. Ltd. have described proteolysis targeting chimeric (PROTAC) compounds comprising cereblon (CRBN) ligands ...

Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed ...

Dupilumab had a fivefold improvement in sustained disease remission in bullous pemphigoid compared with placebo, along with a significant reduction in oral corticosteroid use.

is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL4) and interleukin-13 (IL13) pathways and is not an immunosuppressant. The Dupixent development program has ...